Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pharmacokinetics and Pharmacodynamics of the Antiplatelet Combination Aspirin (Acetylsalicylic Acid) Plus Extended-Release Dipyridamole Are Not Altered by Coadministration with the Potent CYP2C19 Inhibitor Omeprazole

Pharmacokinetics and Pharmacodynamics of the Antiplatelet Combination Aspirin (Acetylsalicylic... Am J Cardiovasc Drugs (2013) 13:113–120 DOI 10.1007/s40256-013-0018-3 OR IGINAL RESEARCH ARTIC L E Pharmacokinetics and Pharmacodynamics of the Antiplatelet Combination Aspirin (Acetylsalicylic Acid) Plus Extended-Release Dipyridamole Are Not Altered by Coadministration with the Potent CYP2C19 Inhibitor Omeprazole • • Elliot Offman Michael J. Schobelock • • Rolf Brickl Cam P. VanderMaelen Jerome Ehrlich Wolfgang Eisert Published online: 27 March 2013 Springer International Publishing Switzerland 2013 Abstract Participants Sixty healthy male and female volunteers Background The fixed-dose combination of aspirin aged 18–50 years were included in the study. (acetylsalicylic acid) 25 mg plus extended-release dipy- Intervention Participants were randomized to one of two ridamole 200 mg (ASA ? ER-DP) is used for long-term treatment sequences (ABCD or CDAB), each compris- secondary stroke prevention in patients who have experi- ing four 7-day treatments with a washout of C14 days enced non-cardioembolic stroke or transient ischemic between the second and third treatments. Treatment attack. Although the theoretical risk is low that the anti- A = ASA ? ER-DP 25 mg/200 mg (Aggrenox ) twice platelet activity of ASA ? ER-DP will be affected by daily (BID) alone; B = ASA ? ER-DP 25 mg/200 mg concomitant use of a proton pump http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Pharmacokinetics and Pharmacodynamics of the Antiplatelet Combination Aspirin (Acetylsalicylic Acid) Plus Extended-Release Dipyridamole Are Not Altered by Coadministration with the Potent CYP2C19 Inhibitor Omeprazole

Loading next page...
 
/lp/springer-journals/pharmacokinetics-and-pharmacodynamics-of-the-antiplatelet-combination-ZfUlZIoycM

References (27)

Publisher
Springer Journals
Copyright
Copyright © 2013 by Springer International Publishing Switzerland
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/s40256-013-0018-3
pmid
23532686
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs (2013) 13:113–120 DOI 10.1007/s40256-013-0018-3 OR IGINAL RESEARCH ARTIC L E Pharmacokinetics and Pharmacodynamics of the Antiplatelet Combination Aspirin (Acetylsalicylic Acid) Plus Extended-Release Dipyridamole Are Not Altered by Coadministration with the Potent CYP2C19 Inhibitor Omeprazole • • Elliot Offman Michael J. Schobelock • • Rolf Brickl Cam P. VanderMaelen Jerome Ehrlich Wolfgang Eisert Published online: 27 March 2013 Springer International Publishing Switzerland 2013 Abstract Participants Sixty healthy male and female volunteers Background The fixed-dose combination of aspirin aged 18–50 years were included in the study. (acetylsalicylic acid) 25 mg plus extended-release dipy- Intervention Participants were randomized to one of two ridamole 200 mg (ASA ? ER-DP) is used for long-term treatment sequences (ABCD or CDAB), each compris- secondary stroke prevention in patients who have experi- ing four 7-day treatments with a washout of C14 days enced non-cardioembolic stroke or transient ischemic between the second and third treatments. Treatment attack. Although the theoretical risk is low that the anti- A = ASA ? ER-DP 25 mg/200 mg (Aggrenox ) twice platelet activity of ASA ? ER-DP will be affected by daily (BID) alone; B = ASA ? ER-DP 25 mg/200 mg concomitant use of a proton pump

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Mar 27, 2013

There are no references for this article.